Dr. Solow has held numerous roles over her ten years at Emergent, including senior vice president of research & development and Gaithersburg site head. She has played a key role in successfully securing more than $4 billion in funding and in expanding the R&D portfolio from anthrax vaccines to a broad spectrum of medical countermeasures.
From 2006-2008 Dr. Solow was a principal consultant with PRTM, a management consulting firm where she led and worked on teams focused on U.S. government and commercial projects related to healthcare, biotechnology, and biodefense including strategy, implementation of best management practices, portfolio management, end-to-end product development, and proposal management/ preparation. From 2003-2006 Dr. Solow served as director, business development with DynPort Vaccine Company, where in less than three years, she expanded a “one contract” biotechnology company into three new product lines and two new U.S. government agencies by creating an opportunity pipeline, devising a marketing strategy, and then leading a team to win two grants and four contracts from competitive procurements totaling more than $300 million. Dr. Solow has also held various scientific positions such as senior scientist, DynPort Vaccine Company (2001-2003) and research scientist with the U.S. Department of Agriculture (1998-2001).
Dr. Solow was a postdoctoral research fellow at University of Pennsylvania, where she focused her research on diabetes and insulin signaling. Dr. Solow received her Ph.D. in Biochemistry from Virginia Polytechnic Institute and State University, her Masters in Animal Sciences from the University of Kentucky and her Bachelors in Science from University of Illinois at Urbana-Champaign. She has 13 peer-reviewed publications and a patent.